Pharmaceuticals

Last January, Anderson Ata became the seventh person in the world to receive teplizumab, which researchers say is the first big milestone in treating diabetes since the first production of insulin over 100 years ago.

Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.

The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.

A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.

Many widely prescribed drugs and over-the-counter medications work differently in people who are obese, but exactly how and at what dose often isn't clear.

A Tampa-area mom couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.

Drug and staffing shortages remain, and stores are dealing with a new vaccine and insurance coverage for COVID shots. Some have addressed challenges, but customers can expert slower service and lines.

The point isn’t that Donald Trump managed drug shortages badly as president or that Joe Biden is handling them badly now, experts said. Many factors contribute to the problem.

A federal audit found lax oversight and multiple cases of child welfare workers failing to follow state regulations on psychotropic or opioid medication.

The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors.